0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T21:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.25900M | -1.88500M | 18.57M | 22.98M | 20.34M |
| Minority interest | - | - | - | - | - |
| Net income | -2.32100M | -2.23000M | 17.14M | 22.25M | 22.30M |
| Selling general administrative | 12.80M | 12.64M | 10.14M | 9.19M | 8.53M |
| Selling and marketing expenses | 15.28M | 6.28M | 4.52M | 4.37M | 3.63M |
| Gross profit | 46.70M | 30.33M | 47.55M | 49.74M | 41.47M |
| Reconciled depreciation | 12.15M | 5.61M | 4.90M | 4.52M | 3.70M |
| Ebit | -1.64300M | -0.40100M | 19.24M | 22.78M | 20.08M |
| Ebitda | 10.51M | 5.21M | 25.16M | 28.45M | 23.78M |
| Depreciation and amortization | 12.15M | 5.61M | 5.92M | 5.67M | 3.70M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -1.64300M | -0.40100M | 19.24M | 22.78M | 19.26M |
| Other operating expenses | 124.81M | 104.34M | 114.01M | 104.40M | 95.21M |
| Interest expense | 0.91M | 1.28M | 0.27M | 0.29M | 0.34M |
| Tax provision | 0.06M | 0.34M | 1.43M | 0.73M | -1.95500M |
| Interest income | 0.09M | 0.29M | 1.03M | 1.15M | 0.82M |
| Net interest income | -0.82300M | -0.98200M | 0.76M | 0.85M | 0.48M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.06M | 0.34M | 1.43M | 0.73M | -1.95500M |
| Total revenue | 129.34M | 103.64M | 133.25M | 127.19M | 114.47M |
| Total operating expenses | 42.17M | 31.02M | 28.32M | 26.95M | 22.21M |
| Cost of revenue | 82.64M | 73.31M | 85.69M | 77.45M | 73.00M |
| Total other income expense net | -0.61600M | -1.48400M | -0.67200M | 0.20M | 0.60M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.32100M | -2.23000M | 17.14M | 22.25M | 22.30M |
| Net income applicable to common shares | -2.32100M | -2.23000M | 17.14M | 22.25M | 22.30M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 351.97M | 322.38M | 318.67M | 210.66M | 173.80M |
| Intangible assets | 109.64M | 116.70M | 153.59M | 1.49M | 0.30M |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.37M | 3.88M | 8.87M | 4.52M | 3.27M |
| Total liab | 109.97M | 146.36M | 141.84M | 32.03M | 38.48M |
| Total stockholder equity | 242.00M | 176.02M | 176.82M | 178.64M | 135.32M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 23.06M | 37.29M | 25.13M | 5.52M | 5.81M |
| Common stock | 14.90M | 11.73M | 11.72M | 11.71M | 10.43M |
| Capital stock | 15.02M | 11.73M | 11.72M | 11.71M | 10.43M |
| Retained earnings | -39.86730M | -48.48400M | -46.16300M | -43.93300M | -61.07300M |
| Other liab | - | 55.51M | 67.22M | 3.43M | 1.50M |
| Good will | 30.06M | 30.31M | 0.07M | - | - |
| Other assets | 0.00000M | 7.64M | 5.63M | 2.14M | 1.36M |
| Cash | 55.18M | 34.26M | 18.59M | 70.20M | 42.66M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 49.18M | 75.70M | 54.06M | 24.97M | 32.74M |
| Current deferred revenue | 0.15M | 0.04M | 0.04M | 2.02M | 0.59M |
| Net debt | -46.43152M | -13.65800M | 5.76M | -65.25800M | -36.91500M |
| Short term debt | 1.37M | 5.46M | 3.79M | 1.31M | 1.51M |
| Short long term debt | - | 4.44M | 20.62M | 0.24M | 0.49M |
| Short long term debt total | 8.75M | 20.60M | 24.35M | 4.94M | 5.75M |
| Other stockholder equity | 263.65M | 216.00M | 214.85M | 214.32M | 189.66M |
| Property plant equipment | - | 28.73M | 29.40M | 29.12M | 28.57M |
| Total current assets | 168.56M | 139.00M | 130.04M | 177.91M | 143.56M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 29.01M | 23.23M | 177.15M | 135.02M |
| Short term investments | - | - | 0.00000M | 39.07M | 31.25M |
| Net receivables | 21.26M | 35.96M | 44.03M | 26.63M | 26.48M |
| Long term debt | - | 12.96M | 17.41M | 0.04M | 0.26M |
| Inventory | 87.75M | 68.78M | 67.42M | 42.02M | 43.17M |
| Accounts payable | 24.60M | 32.92M | 25.10M | 16.11M | 24.83M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 3.32M | -3.23000M | -3.58500M | -3.45300M | -3.69600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 11.71M | 10.43M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.51M | 7.58M | 5.56M | 2.14M | 0.35M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 183.41M | 183.37M | 188.62M | 32.75M | 30.23M |
| Capital lease obligations | 8.82M | 3.19M | 4.31M | 4.67M | 5.00M |
| Long term debt total | - | - | - | - | 4.24M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -3.78400M | 39.08M | -13.12700M | -0.56400M | -5.17600M |
| Change to liabilities | 7.04M | 9.73M | -8.35600M | 5.98M | -6.37200M |
| Total cashflows from investing activities | -3.78400M | -61.05000M | -13.12700M | -0.56400M | -5.17600M |
| Net borrowings | -3.72600M | 18.57M | -1.59500M | -1.54600M | -0.59600M |
| Total cash from financing activities | -9.34300M | 18.59M | 23.36M | -1.53000M | -0.58700M |
| Change to operating activities | -1.62800M | -8.90900M | -1.23400M | 1.05M | -1.75900M |
| Net income | -2.32100M | -2.23000M | 17.14M | 22.25M | 22.30M |
| Change in cash | 15.67M | -51.34000M | 27.54M | 24.57M | 5.41M |
| Begin period cash flow | 18.59M | 70.20M | 42.66M | 18.09M | 12.68M |
| End period cash flow | 34.26M | 18.86M | 70.20M | 42.66M | 18.09M |
| Total cash from operating activities | 28.59M | -8.81900M | 19.11M | 27.57M | 10.55M |
| Issuance of capital stock | 0.00000M | 0.00000M | - | - | - |
| Depreciation | 12.15M | 5.61M | 4.90M | 4.52M | 3.70M |
| Other cashflows from investing activities | - | - | - | 1.74M | -2.29200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.36100M | -2.37300M | 1.16M | -13.85700M | -8.24600M |
| Change to account receivables | 7.60M | -12.86100M | 1.33M | 5.12M | 2.31M |
| Sale purchase of stock | - | - | - | 0.02M | 0.00900M |
| Other cashflows from financing activities | 0.00900M | 20.02M | 24.96M | 0.02M | 0.00900M |
| Change to netincome | 7.10M | 2.21M | 4.17M | 2.52M | -1.38700M |
| Capital expenditures | 3.78M | 3.73M | 5.49M | 2.30M | 2.88M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 11.65M | -14.41100M | -7.10100M | -1.71600M | -14.06600M |
| Stock based compensation | 1.15M | 0.53M | 0.98M | 1.16M | 0.95M |
| Other non cash items | 5.89M | 1.34M | 1.77M | 0.62M | -0.38000M |
| Free cash flow | 24.80M | -12.54900M | 13.62M | 25.27M | 7.66M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KMDA Kamada |
0.03 0.52% | 5.85 | 22.78 | 19.49 | 2.08 | 1.22 | 1.76 | 11.20 |
| ZTS Zoetis Inc |
1.04 0.59% | 176.71 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.24 0.82% | 29.07 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
1.70 1.20% | 143.75 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.04 0.30% | 13.33 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
2 Holzman Street, Rehovot, Israel, 7670402
| Name | Title | Year Born |
|---|---|---|
| Mr. Amir London | Chief Exec. Officer | 1969 |
| Mr. Chaime Orlev | Chief Financial Officer | 1970 |
| Mr. Eran Nir | Chief Operating Officer | 1973 |
| Ms. Yifat Philip Esq. | VP of Legal, Gen. Counsel & Corp. Sec. | 1977 |
| Mr. David Tsur | Co-Founder & Deputy Chairman | 1950 |
| Ms. Hanni Neheman | VP of Marketing & Sales | 1970 |
| Ms. Ariella Raban | VP of HR | 1976 |
| Mr. Jon R. Knight | VP of US Commercial Operations | NA |
| Mr. Amir London | Chief Executive Officer | 1969 |
| Mr. Jon R. Knight | Vice President of US Commercial Operations | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...